WaveMan
WaveMan · Company
TARA · Protara Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TARA Protara Therapeutics (TARA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001359931
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
75
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $412.0K priced

What the filings say about TARA

Insiders, 180 days
-$882.2K net sold
1 seller · 0% of sales under a 10b5-1 plan

Protara Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Protara Therapeutics, Inc. insiders sold a net $882.2K of stock across 75 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Shefferman Jesse
CEO and President
SELL
2026-07-01 SECtraded 2026-06-29
215,687
$882.2K
-42.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 11, 2022.
  • The trade is 29.9% of the 721,832 shares held after it.
  • No other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Shefferman Jesse sold about $882.2K of TARA on Jun 29, 2026, the largest insider sale at the company on our record; 75 funds added in the latest 13F quarter.
Zummo Jacqueline
Chief R&D Officer
SELL
2026-04-09 SECtraded 2026-04-08
1,134
$6.1K
-52.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 1, 2026.
  • The trade is 1.2% of the 94,827 shares held after it.
  • No other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief R&D Officer Zummo Jacqueline sold about $6.1K of TARA on Apr 8, 2026; 75 funds added in the latest 13F quarter.
Zummo Jacqueline
Chief R&D Officer
SELL
2026-04-02 SECtraded 2026-04-01
22,598
$118.9K
-53.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 26, 2025.
  • The trade is 23.5% of the 95,961 shares held after it.
  • No other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief R&D Officer Zummo Jacqueline sold about $118.9K of TARA on Apr 1, 2026, the largest insider sale at the company since 2024; 75 funds added in the latest 13F quarter.
Levy Richard S
Director
BUY
2025-05-19 SECtraded 2025-05-14
20,000
$63.8K
-32.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 39.2% of the 51,000 shares held after it.
  • No other insider bought within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Levy Richard S bought about $63.8K of TARA on May 14, 2025, the largest insider purchase at the company since 2022; 75 funds added in the latest 13F quarter.
Zummo Jacqueline
Chf Scientific Operations Off
SELL
2025-03-28 SECtraded 2025-03-26
21,224
$96.1K
-44.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 21.5% of the 98,861 shares held after it.
  • No other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chf Scientific Operations Off Zummo Jacqueline sold about $96.1K of TARA on Mar 26, 2025; 75 funds added in the latest 13F quarter.
75 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 70 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$882.2K over 180 days
below 61% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
75 funds bought in last quarter
more than 58% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.1% of the float short (float per yahoo 2026-10-27) · 4.3 days to cover · settled 2026-10-15
more than 73% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TARA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-54.5%12M
-55%-21%+13%+47%2025-102025-122026-022026-042026-062026-082026-10 2026-06-29 · Shefferman Jesse sold $882.2K2026-04-01 · Zummo Jacqueline sold $118.9K2026-04-08 · Zummo Jacqueline sold $6.1K2026-06-29 · JESSE SHEFFERMAN filed to sell $882.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TARA: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
4,696,709 sh
$17.9M
BlackRock, Inc.
3,663,499 sh
$14.0M
MILLENNIUM MANAGEMENT LLC
3,101,166 sh
$11.8M
Velan Capital Investment Management LP
2,844,652 sh
$10.9M
VANGUARD CAPITAL MANAGEMENT LLC
2,300,133 sh
$8.8M

Congress trades in TARA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TARA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JESSE SHEFFERMAN
Filed 2026-06-29
$882.0K

TARA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$298.0K position · as of 2026-06-30
0.2%
ALPS Medical Breakthroughs ETF
$259.2K position · as of 2026-05-31
0.2%
Columbia Small Cap Value Discovery Fund
$3.0M position · as of 2026-07-31
0.1%
Small Cap Value Fund
$449.5K position · as of 2026-06-30
0.1%
NVIT Small Cap Value Fund
$100.5K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$671.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
2
Phase 2
2 active
1
Phase 3
1 active
1
Not applicable
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $882.2K sold by insiders over 180 days, 75 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TARA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$66.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
current debt only, 2021-12-31 (54 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-45.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-42.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-49.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$121.8M
market value at close 2026-10-26 on 2026-08-07 shares, plus current debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
FCF yield
-47.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$64.5M-$49.2M-$43.6M-$67.1M
Net income-$57.4M-$44.6M-$40.4M-$66.0M
EPS (diluted)-1.34-2.17-3.57-5.86
Operating cash flow-$56.4M-$35.8M-$37.6M-$26.5M
Cash$49.7M$162.8M$39.6M$24.1M
Buybacksn/an/a$91.0K$90.0K
SEC XBRL, fiscal years, as known on 2026-10-28

TARA Stock Sonar score 5/7 axes

Find similar shapesCompare

TARA ranks highest on financial health (99th percentile) and institutional and government (58th), and lowest on insider conviction (19th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
53
Inputs
  • Return on equity-45.8% · 57 pct, sector of 545
  • Return on assets-42.0% · 51 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-49.6% · 51 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Insider conviction
19
Inputs
  • Net Form 4 buying (codes P and S), 180d-$882K · 37 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
58
Inputs
  • Funds adding, latest quarter75 · 58 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
36
Inputs
  • Short interest, % of float+11.1% · 36 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TARA filings, in plain words

Are Protara Therapeutics insiders buying or selling TARA?

In the 180 days to 2026-10-28, Protara Therapeutics insiders were net sellers, a net $882.2K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Protara Therapeutics insiders were net sellers of TARA, a net $882.2K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies